Calcium-activated potassium channels, also known as calcium-dependent potassium channels, play a crucial role in cellular signaling and the regulation of membrane potential. Calcium-activated potassium (KCa) channels respond to intracellular Ca2+ concentration changes
opening in response to elevated Ca2+ levels. By allowing the outward flow of K+ ions, the cell membrane is hyperpolarized, leading to reduced excitability and repolarization. KCa channels are widely distributed throughout various tissues and cell types, highlighting their significance in diverse physiological processes.
KCa channels are typically composed of four pore-forming α subunits, which can assemble in various combinations with β subunits, leading to the formation of different channel types with distinct properties. KCa channels can be classified into three main groups: small-conductance (SK), intermediate conductance (IK), and Ca-channels”>large conductance (BK) channels. SK channels are abundant in the central nervous system (CNS), where they modulate synaptic plasticity and contribute to learning and memory processes. IK channels are prevalent in smooth muscle cells and immune cells, where they influence vascular tone and immune responses. BK channels are found in smooth muscles, neurons, and the inner ear, regulating vascular tone, neuronal excitability, and hearing, respectively. The unique structures and locations of KCa channels are important for elucidating their roles in specific cellular processes.
KCa Channel Disorders
KCa channel mutations have been linked to various diseases and disorders, underscoring the importance of these channels in maintaining cellular homeostasis. Altered channel activity due to mutations can lead to abnormal Ca2+ signaling and disrupted K+ flow, causing neuronal hyperexcitability or impaired vascular function. For instance, mutations in the KCNMA1 gene, which encodes the BK channel, have been associated with epilepsy, paroxysmal dyskinesias, and hypertension. The clinical manifestations of KCa channel-related diseases can vary widely depending on the affected tissue and the specific mutation, and treatment options often focus on symptom management. Further research is needed to discover potential therapeutics for more effective treatment.
KCa channels continue to be an area of active research given their significance in cellular physiology and their association with various diseases. Scientists are exploring novel therapeutic strategies that modulate KCa channel activity to address neurological and cardiovascular disorders effectively. Targeting KCa channels to restore normal function or alleviate symptoms holds promise for developing precision therapies.
KCa Channel Antibodies
KCa channel antibodies are designed to specifically target and bind to the various subunits of KCa channels, allowing researchers to detect and quantify their expression levels in different tissues and cell types. By utilizing KCa channel antibodies in techniques like immunohistochemistry and Western blot, scientists can visualize the spatial distribution of KCa channels within tissues and study their expression patterns under different physiological and pathological conditions. KCa channel antibodies enable researchers to investigate the impact of mutations or post-translational modifications on KCa channel function.
The availability of high-quality KCa channel antibodies has significantly advanced the understanding of the involvement of KCa channels in diverse cellular processes, such as neurotransmitter release, smooth muscle contractility, and immune responses. The utilization of KCa channel antibodies in research has the potential to reveal novel therapeutic targets for addressing diseases linked to KCa channel dysfunction, leading to the development of effective targeted treatments. Alomone Labs offers a range of KCa channel antibodies, blockers, activators, and more, providing the necessary tools for studying KCa channels.
|Anti-KCNMA1 (KCa1.1) | Rabbit | Polyclonal | #APC-021|
|Anti-KCNMA1 (KCa1.1) | Guinea pig | Polyclonal | #APC-021-GP|
|Anti-KCNMA1 (KCa1.1) | Rabbit | Polyclonal | #APC-107|
|Anti-KCNMA1 (KCa1.1) (extracellular) | Rabbit | Polyclonal | #APC-151|
|Anti-KCNN1 (KCa2.1, SK1) | Rabbit | Polyclonal | #APC-039|
|Anti-KCNN2 (KCa2.2, SK2) | Rabbit | Polyclonal | #APC-028|
|Anti-KCNN2 (KCa2.2, SK2) | Guinea pig | Polyclonal | #APC-028-GP|
|Anti-KCNN3 (KCa2.3, SK3) (N-term) | Rabbit | Polyclonal | #APC-025|
|Anti-KCNN3 (KCa2.3, SK3) (C-term) | Rabbit | Polyclonal | #APC-103|
|Anti-KCNN4 (KCa3.1, SK4) | Rabbit | Polyclonal | #APC-064|
|Anti-KCNN4 (KCa3.1, SK4) (extracellular) | Mouse | Monoclonal | #ALM-051|
|Anti-sloβ1 (KCNMB1) | Rabbit | Polyclonal | #APC-036|
|Anti-sloβ2 (KCNMB2) | Rabbit | Polyclonal | #APC-034|
|Anti-sloβ3 (KCNMB3) (extracellular) | Rabbit | Polyclonal | #APC-068|
|Anti-sloβ4 (KCNMB4) | Rabbit | Polyclonal | #APC-061|
|Anti-LRRC26 | Rabbit | Polyclonal | #APC-070|
|Anti-LINGO-1 (extracellular) | Rabbit | Polyclonal | #ANT-032|
|Anti-KCNN3 (KCa2.3, SK3) (N-term)-ATTO Fluor-594 | Rabbit | Polyclonal | #APC-025-AR|
|Anti-KCNN4 (KCa3.1, SK4) (extracellular)-ATTO Fluor-488 | Mouse | Monoclonal | #ALM-051-AG|
|Anti-KCNN4 (KCa3.1, SK4) (extracellular)-Biotin | Mouse | Monoclonal | #ALM-051-B|
|Anti-KCNN4 (KCa3.1, SK4) (extracellular)-FITC | Mouse | Monoclonal | #ALM-051-F|
|Isopimaric Acid | KCa1.1 | Activator | #I-370|
|NS-1619 | KCa1.1 | Activator | #N-105|
|NS-11021 | KCa1.1 | Activator | #N-335|
|NS19504 | KCa1.1 | Activator | #N-235|
|Pimaric Acid | KCa1.1 | Activator | #P-270|
|Tanshinone II-A sodium sulfonate | KCa1.1 | Activator | #T-165|
|Paxilline | KCa1.1 | Blocker | #P-450|
|Verruculogen | KCa1.1 | Blocker | #V-500|
|Penitrem A | KCa1.1 | Blocker | #P-650|
|1-EBIO | KCa3.1 | Activator | #E-150|
|SKA-121 | KCa3.1 | Activator | #S-245|
|NS-309 | KCa3.1 | Activator | #N-180|
|NS-6180 | KCa3.1 | Blocker | #N-230|
|TRAM 34 | KCa3.1 | Blocker | #T-105|
|NS-4591 | KCa2.1-2.3, 3.1 | Activator | #N-325|
|SKA-31 | KCa2.1-2.3, 3.1 | Activator | #S-120|
|NS8593 | KCa2.1-2.3 | Blocker | #N-196|
|NS8593 hydrochloride | KCa2.1-2.3 | Blocker | #N-195|
|CyPPA | KCa2.1-2.2 | Activator | #C-110|